Sarepta released three‑year follow‑up data for Elevidys (delandistrogene moxeparvovec) showing durable efficacy across motor function assessments versus external controls, with the gap widening between years two and three. The company presented long‑term follow‑up from the pivotal Embark study and argued the results support a growing efficacy narrative after a year‑one miss and subsequent safety and labeling challenges. Sarepta executives and clinicians noted a 70%+ reduction in decline compared with historical controls on key endpoints, prompting positive reactions from some Wall Street analysts and a share price uptick. The data arrive as Sarepta seeks to restore confidence in commercial uptake and translate durability into renewed sales momentum.